ERAXIS
Drug
PFIZER INC.
Total Payments
$164,177
Transactions
80
Doctors
27
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $8,400 | 1 | 0 |
| 2019 | $68,188 | 39 | 22 |
| 2018 | $31,060 | 14 | 1 |
| 2017 | $56,529 | 26 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $76,874 | 35 | 46.8% |
| Consulting Fee | $73,415 | 25 | 44.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,190 | 7 | 8.0% |
| Travel and Lodging | $593.69 | 6 | 0.4% |
| Food and Beverage | $105.01 | 7 | 0.1% |
Payments by Type
General
$87,303
45 transactions
Research
$76,874
35 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PROSPECTIVE OPENLABEL STUDY TO ASSESS THE PHARMACOKINETICS SAFETY EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS INCLUDING CANDIDEMIA | PFIZER INC. | $76,874 | 0 |
Ad
Manufacturing Companies
- PFIZER INC. $164,177
Product Information
- Type Drug
- Total Payments $164,177
- Total Doctors 27
- Transactions 80
About ERAXIS
ERAXIS is a drug associated with $164,177 in payments to 27 healthcare providers, recorded across 80 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2017 to 2020. In 2020, $8,400 was paid across 1 transactions to 0 doctors.
The most common payment nature for ERAXIS is "Unspecified" ($76,874, 46.8% of total).
ERAXIS is associated with 1 research study, including "A PROSPECTIVE OPENLABEL STUDY TO ASSESS THE PHARMACOKINETICS SAFETY EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS INCLUDING CANDIDEMIA" ($76,874).